Synerkine Pharma receives European Orphan Drug Designation for SK-01 to treat Complex Regional Pain Syndrome
Synerkine today announced that the European Commission has granted the Orphan Drug Designation (ODD) for SK-01, the company’s most advanced development program, to treat complex regional pain syndrome (CRPS).